Our actual results may differ materially from these plans and expectations, and the impact and duration of the COVID-19 pandemic is unknown.
Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are our financial measures that are not defined under generally accepted accounting principles.
Before I begin the detailed third quarter discussion, I would like to ask Andy Last, our Chief Operating Officer, to provide an update on Bio-Rad's operations in light of the current pandemic-related environment that we are experiencing globally.
Annette's efforts and leadership have contributed to significant growth for the Life Science Group and Bio-Rad, and the company has started a search for a successor, and we will provide an update in the coming months.
We're now entering the seventh consecutive quarter of operating within the COVID pandemic, and so I shall make my comments brief as we have now established an operating cadence with embedded employee safety practices.
Our end markets continued to show improvement during Q3, with demand pickup in both life science and diagnostic markets in all regions.
We are believing -- we believe we are maintaining our commitment to a safe workplace for all our employees.
As we enter Q4, we expect COVID-related demand for our products to be sequentially lower.
